Sheet 1 of 1

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
**OC01629K**APPLICATION NO.:  
**10/664,337****INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**APPLICANT:  
**Michael P. Dwyer et al.***(Use several sheets if necessary)*FILING DATE:  
**09/17/2003**GROUP:  
**1614****U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
	AL	<b>WO 02/50079</b>	<b>06/27/2002</b>	<b>WIPO</b>				
	AM	<b>WO 97/16452</b>	<b>05/09/1997</b>	<b>WIPO</b>				
	AN							
	AO							
	AP							


**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	AQ	Nathanael Gray et al., "ATP-site Directed Inhibitors of Cyclin-dependent Kinases", <i>Current Medicinal Chemistry</i> , 6(9): 859-875, (1999).
	AR	Adrian M. Senderowicz et al., "Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators", <i>Journal of the National Cancer Institute</i> , 92(5): 376-387 (March 1, 2000).
	AS	
	AT	
	AU	
	AV	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



POTENTIAL TO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
**OC01629K**APPLICATION NO.:  
**10/664,337**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANTAPPLICANT:  
**Michael P. Dwyer et al.**FILING DATE:  
**09/17/2003**

GROUP:

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA	US 6,107,305	08/22/2000	Misra et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
	AL	WO 01/35917	05/25/2001	PCT				
	AM							
	AN							
	AO							
	AP							

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AQ	Vesely et al., "Inhibition of Cyclin-Dependent Kinases by Purine Analogues", <i>Eur. J. Biochem</i> (1994), 224: 771-786.
	AR	Senderowicz et al., "Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients With Refractory Neoplasms", <i>Journal of Clinical Oncology</i> (September 1998), 16(9): 2986-2999.
	AS	Meijer et al., "Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5", <i>Eur. J. Biochem.</i> (1997), 243: 527-536.
	AT	Bible et al., "Cytotoxic Synergy between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration", <i>Cancer Research</i> (August 15, 1997), 57: 3375-3380.
	AU	Shiota et al., "Synthesis and Structure-Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo[1,5- $\alpha$ ]pyrimidine", <i>Chem. Pharm. Bull.</i> (1999), 47(7): 928-938.
	AV	Yasuo Makisumi et al., "Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted Pyrazolo[1,5- $\alpha$ ]pyrimidines.", <i>Chem Pharm. Bull.</i> (1962), 10: 620-626.
	AW	Aboul-Fadi et al., "Effective and Variable Functionalization of Pyrazolo[1,5- $\alpha$ ]pyridines Involving Palladium-Catalyzed Coupling Reactions", <i>Synthesis</i> 2000, (12): 1727-1732.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.